Letybo: A New Neuromodulator Enters the U.S. Market, But We're Watching First

At The Confidence Lab, we're always excited to see what's new int he world of aesthetics but we're just as committed to maintaining high standards when it comes to introducing new products to our patients and trainees.

One of the newest players to enter the U.S. neuromodulator market is Letybo, which received FDA approval in 2024 for the treatment of frown lines. Manufactured by Hugel, a South Korean aesthetics company, Letybo is already a household name overseas. Known as Botulax in Korea, it has been used there for nearly a decade.

In Korea, Letybo is hugely popular and is often bundled into "combination therapy" treatments and skin boosters. We love those treatments here at The Confidence Bar too, but the high cost of using large doses across the skin to achieve that glowing effect can be price gouging for practice and patient. Now, with a more affordable product like Letybo entering the market, there's real appeal offering comparable results to other toxins at a more accessible price point.

So, what does this mean for us here in the States?

What We Know (So Far):

• Letybo is now the sixth FDA-approved neuromodulator in the U.S., joining Botox, Dysport, Xeomin, Jeuveau, and Daxxify.

• Early adopters in the U.S. report a slightly faster onset - though we've heard similar claims before with every new toxin, so we avoid overpromising to patients.

• Longevity results are mixed, based on feedback from colleagues in Australia: some report it lasting similarly to Botox, while others say it fades quicker.

• Pricing: It's significantly more affordable than Botox, which could make it a more accessible option for both patients and practices.

Why We're Waiting (But Excited!)

While it's tempting to jump on to something new especially when it comes from beauty-forward markets like Korea, we believe in a measured, reasonable approach. At The Confidence Lab, we always test products on ourselves first, then with our most trusted patients for honest feedback, before incorporating them into our treatment room or training programs.

We're closely watching how trusted peers, and their patients respond, looking for consistent efficacy, predictable longevity, and any unexpected side effects (high price point is not one of them). Of course, we value what clinical trials tell us, but real-world use is so valuable.

What's Next?

We'll continue to follow Letybo's rollout in the U.S. with curiosity and a little excitement, as with any new product. But we are never the first bull in the china shop.

Stay tuned!